Companion Diagnostics Market Size & Share 2026-2035

Companion Diagnostics Market Size

The global companion diagnostics market was valued at USD 7.9 billion in 2025, rising USD 8.7 billion in 2026, and is projected to reach USD 22.5 billion by 2035 at an approximately 11.2% CAGR from 2026 to 2035. Growth reflects a change in how targeted therapies are developed and commercialized: biomarker selection is increasingly embedded in trial design, regulatory evidence, labeling, and treatment access rather than added after a drug reaches the market.

Companion diagnostics identify patients likely to benefit from a therapy, face elevated treatment risk, or require monitoring based on a defined biomarker. The market includes instruments, consumables, and software and services used across NGS, PCR, ISH, and IHC workflows. Cancer remains the central demand base. IARC estimated 20 million new cancer cases and 9.7 million cancer deaths globally in 2022 and projects that annual new cases could exceed 35 million by 2050.^{[1]World Health Organization / International Agency for Research on Cancer, "Global cancer burden growing, amidst mounting need for services," who.int} The increasing number of biomarker-defined therapies turns that disease burden into recurring requirements for tumor characterization, confirmatory testing, and, in some cases, resistance monitoring.

FDA oncology approvals illustrate the intensity of this linkage. A peer-reviewed review found that 78 of 217 FDA-approved oncology and hematology new molecular entities from 1998 through 2024 were associated with at least one FDA-approved companion diagnostic; the share rose from 15% of oncology NMEs in 1998–2010 to 42% in 2011–2024.^{[2]Frontiers in Oncology, "An analysis of FDA drug approvals for oncological hematological malignancies in relation to companion diagnostics," frontiersin.org} That shift favors platforms able to add new biomarker-drug claims without rebuilding a laboratory's testing infrastructure.

Key Drivers

Rising prevalence of cancer Cancer incidence enlarges the population requiring molecular characterization, but the stronger CDx effect comes from the breadth of alterations evaluated within each diagnosed tumor. Lung, breast, colorectal, and other solid tumors increasingly require testing for markers such as EGFR, HER2, KRAS, RET, NTRK, MET, and MSI-H/dMMR before treatment selection. IARC identifies lung cancer, female breast cancer, and colorectal cancer among the highest-incidence cancers globally, creating large underlying testing pools for these workflows.Tumor evolution adds a second demand channel, where progression can require re-testing to assess resistance biology or establish eligibility for a later-line therapy.

Growing incidence of adverse drug reactions Companion diagnostics can support safer use of high-cost therapies by identifying patients for whom a treatment's benefit-risk profile is unfavorable. The CDC reports more than 1.5 million annual emergency department visits for adverse drug events in the United States, with roughly 500,000 resulting in hospitalization.^{[3]Centers for Disease Control and Prevention, "Medication Safety: FastStats, Data and Research," cdc.gov} FDA defines a companion diagnostic as providing information essential for the safe and effective use of a corresponding therapeutic product.^{[4]U.S. Food and Drug Administration, "Companion Diagnostics," fda.gov} In oncology, this connects the diagnostic to both efficacy and toxicity management: a test can prevent use of a targeted therapy in patients without the molecular feature on which its benefit depends.

Growth of precision medicine Regulatory and reimbursement infrastructure is making comprehensive testing more commercially viable. FDA's oncology program continues to develop approaches for biomarker use in oncology drug development, including guidance concerning circulating tumor DNA as a biomarker in curative-intent settings.^{[5]U.S. Food and Drug Administration, "Ongoing Clinical Oncology Projects 2024, 2024 OCE Annual Report," fda.gov} Meanwhile, Illumina's August 2024 FDA authorization for TruSight Oncology Comprehensive created a distributable comprehensive genomic profiling IVD with companion-diagnostic claims, broadening access beyond centralized reference laboratories.^{[6]Illumina, "FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies," investor.illumina.com} NCI precision-medicine trials have demonstrated the operational infrastructure needed to match genomic findings with treatment arms across clinical sites.^{[7]National Cancer Institute, "NCI Precision Medicine Trials," dctd.cancer.gov}

Pharmaceutical firms increasingly embedding companion diagnostics in drug development Parallel development of a drug and its companion diagnostic reduces the risk that a therapy reaches approval without an authorized method to identify the indicated population. Of the CDx-linked oncology NMEs identified in the FDA approval review, 52 received simultaneous drug and diagnostic approval, while delayed diagnostic approvals created an average gap of 707 days in tissue-agnostic indications.Roche reports collaborations with more than 85 pharmaceutical partners, while QIAGEN describes companion-diagnostic partnerships across PCR and emerging digital-PCR programs.^{[8]Roche Diagnostics, "Companion Diagnostics (CDx)," diagnostics.roche.com} These arrangements make pharmaceutical sponsors the largest end-use group because they fund assay development, trial testing, and validation well before routine clinical rollout.

Rising ADC and immuno-oncology approvals requiring companion diagnostics ADC development is tightening the relationship between antigen measurement and treatment access. Roche's PATHWAY HER2 (4B5) assay received FDA approval in January 2025 to identify HR-positive, HER2-ultralow metastatic breast cancer patients eligible for ENHERTU.^{[9]Roche, "Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU," roche.com} Roche also received FDA Breakthrough Device Designation in April 2025 for the VENTANA TROP2 (EPR20043) RxDx Device, which combines an IHC assay with a digital pathology algorithm for NSCLC tissue. Immuno-oncology maintains parallel demand through PD-L1, MSI-H/dMMR, and tumor mutational burden testing, reinforcing a mixed technology market.

Key Restraints

High development costs CDx development requires assay design, analytical validation, clinical bridging, sample access, manufacturing controls, and regulatory coordination with the therapeutic program. In Europe, IVDR requires notified-body assessment for companion diagnostics and consultation with EMA for the associated medicinal product. The EU's 2024 amendment extended transition provisions for certain IVDs, reflecting the practical difficulty of bringing existing products through the new conformity-assessment system on the original timetable.

Limited reimbursement models Regulatory authorization does not ensure routine testing. In the United States, coverage of molecular diagnostics is shaped by Medicare national and local policies, including NCD 90.2 for certain NGS testing in advanced cancer and MolDX local coverage frameworks. In Europe, manufacturers face fragmented national health technology assessment and reimbursement systems, which can delay commercial test uptake even after European-level regulatory clearance is secured.

Companion Diagnostics Market Segment Analysis

By Product

• Instruments: Instruments generated USD 1,947.2 million in 2025, representing 24.6% of market revenue, and are forecast to grow at an 11.5% CAGR. Placements create multi-year commitments to consumables, software, and service contracts. Thermo Fisher's July 2025 FDA authorization for the Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer demonstrated the appeal of decentralized NGS workflows capable of returning results in approximately 24 hours.^{[10]Thermo Fisher Scientific, "Thermo Fisher's NGS Assay Receives FDA Approval as a Companion Diagnostic for ZEGFROVY and for Tumor Profiling," businesswire.com}

• Consumables: Consumables led the market at USD 4,915.4 million, or 62.1%, in 2025 and are forecast to grow at a 10.9% CAGR. Each CDx test consumes platform-specific reagents, probes, antibodies, cartridges, and sample-preparation materials. Multiplexing strengthens this recurring-revenue model because expanded panels support additional therapy claims without requiring another instrument placement.

• Software & Services: Software & services accounted for USD 1,052.7 million in 2025 and are forecast to grow fastest among product categories at an 11.9% CAGR. NGS interpretation, digital pathology algorithms, and co-development services are becoming central as assays generate larger datasets and treatment eligibility is tied to narrower biomarker thresholds.

By Therapy Area

• Cancer: Cancer represented USD 6,229.3 million, or 78.7%, of 2025 revenue and is projected to grow at an 11.4% CAGR. Lung cancer reached USD 1,693.9 million across a biomarker landscape spanning EGFR, ALK, ROS1, KRAS G12C, MET, RET, HER2, and TROP2. Colorectal cancer generated USD 1,852.2 million, breast cancer generated USD 886.5 million, skin cancer contributed USD 625.3 million, and other cancers accounted for USD 2,857.4 million (growing at an 11.9% CAGR).

• Cardiovascular Disease & Neurological Diseases: Cardiovascular disease accounted for USD 751.9 million in 2025, while neurological diseases generated USD 490.7 million. Both remain earlier in their biomarker-stratification cycle than oncology.

• Other Therapy Areas: Other therapy areas, including infectious, rare genetic, and autoimmune conditions, contributed USD 443.3 million and are forecast to expand at a 9.5% CAGR.

By Technology

• NGS: NGS led technology revenue at USD 2,691.2 million, or 34.0%, and is forecast to grow at a 12.1% CAGR. Approvals such as Illumina's TruSight Oncology Comprehensive and Caris Life Sciences' MI Cancer Seek demonstrate the progression toward broad genomic profiling.

• PCR: PCR reached USD 2,232.1 million in 2025 and is forecast to grow at an 11.3% CAGR, favored for its speed, sensitivity, and cost efficiency in focused variant testing and liquid biopsy.

• ISH: ISH represented USD 1,749.3 million in 2025 and is forecast to grow at a 10.0% CAGR, retaining an essential role in gene amplification and rearrangement testing.

• IHC: IHC generated USD 751.9 million in 2025, remaining vital where protein expression and tissue morphology determine eligibility (e.g., HER2, PD-L1, TROP2).

• Other Technologies: Accounted for USD 490.7 million, encompassing emerging cell-based and high-sensitivity platforms.

By End Use

• Pharmaceutical & Biopharma Companies: Led end-use demand at USD 3,031.5 million in 2025 and are forecast to grow at an 11.7% CAGR, driven by upstream co-development, trial enrollment, and assay validation.

• Hospitals: Generated USD 2,232.1 million in 2025, anchored by pathology-led IHC and ISH workflows and decentralized molecular testing.

• Contract Research Organizations (CROs): Represented USD 1,701.8 million in 2025, providing trial site activation, sample logistics, and real-time biomarker testing.

• Diagnostic Laboratories: Accounted for USD 949.8 million in 2025 and are forecast to grow at a 9.3% CAGR.

Companion Diagnostics Market Regional Analysis

North America

North America generated USD 2,636.0 million in 2025, equal to 33.3% of the global market, and is forecast to grow at a 10.8% CAGR. The United States accounted for USD 2,471.2 million, supported by FDA's established co-development framework, high pharma R&D concentration, and Medicare NGS coverage policies.Canada contributed USD 164.8 million and is forecast to grow at a 13.2% CAGR.

Europe

Europe represented USD 2,270.2 million in 2025, or 28.7% of the market, and is forecast to grow at a 10.6% CAGR. IVDR compliance requirements and national reimbursement variations shape adoption across Germany, the UK, France, Spain, Italy, and the Netherlands.

Asia Pacific

Asia Pacific generated USD 2,139.3 million in 2025, or 27.0% of the market, and is forecast to grow fastest at a 12.1% CAGR. China and Japan maintain advancing regulatory frameworks that synchronize drug and diagnostic approvals for large patient populations.

Latin America

Latin America accounted for USD 622.1 million in 2025 and is forecast to grow at an 11.6% CAGR, anchored by private oncology centers and expanding molecular pathology access in Brazil, Mexico, and Argentina.

Middle East & Africa

Middle East & Africa generated USD 247.7 million in 2025 and is projected to expand at an 11.0% CAGR, driven by precision oncology investments in Saudi Arabia and the UAE alongside established private testing networks in South Africa.

Companion Diagnostics Market Share & Competitive Landscape

The market is led by F. Hoffmann-La Roche Ltd, Agilent Technologies, QIAGEN, Abbott Laboratories, and Thermo Fisher Scientific, which collectively account for approximately 55% of global revenue. Their advantage derives from installed laboratory platforms, regulated assay menus, pharmaceutical relationships, and the ability to support a CDx through development, validation, launch, and post-approval label expansion.

Recent Industry Developments

• January 2025 — Roche expanded PATHWAY HER2 (4B5) for HER2-ultralow breast cancer: FDA approved the assay to identify HR-positive, HER2-ultralow metastatic breast cancer patients eligible for ENHERTU.

• April 2025 — Roche received FDA Breakthrough Device Designation for VENTANA TROP2 (EPR20043) RxDx: The device combines an IHC assay with a digital pathology algorithm to quantify TROP2 expression in NSCLC tissue.

• July 2025 — Thermo Fisher received FDA approval for Oncomine Dx Express as a CDx for ZEGFROVY: The assay on the Genexus Dx Integrated Sequencer identifies EGFR exon 20 insertion-positive NSCLC patients eligible for sunvozertinib.

• October 2024 — China approved its first co-developed NGS companion diagnostic for lung cancer: The NMPA authorization paired Burning Rock's LungCure CDx with sunvozertinib for EGFR exon 20 insertion-positive NSCLC.